<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01380769</url>
  </required_header>
  <id_info>
    <org_study_id>CRLX-002</org_study_id>
    <nct_id>NCT01380769</nct_id>
  </id_info>
  <brief_title>A Phase 2 Study of CRLX101 in Patients With Advanced Non-Small Cell Lung Cancer</brief_title>
  <official_title>A Randomized, Phase 2, Study to Assess the Safety and Activity of CRLX101, a Nanoparticle Formulation of Camptothecin, in Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed One or Two Previous Regimens of Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NewLink Genetics Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NewLink Genetics Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare median overall survival of patients with advanced
      non-small cell lung cancer (NSCLC) treated with CRLX101 to patients treated with best
      supportive care (BSC).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lung cancer remains the leading cause of cancer-related mortality in men and women worldwide.
      Non-small cell lung cancer (NSCLC) accounts for approximately 80% of all lung cancer. The
      development of targeted therapies has changed the approach to treating NSCLC significantly
      over the past decade with targeted therapies generally possessing safety advantages over
      traditional cytotoxic regimens. However, combination paradigms and resistance patterns
      complicate the use of these agents. CRLX101 is a nanoparticle comprised of camptothecin (CPT)
      conjugated to a cyclodextrin-based polymer. CRLX101 is designed to increase the exposure of
      tumor cells to CPT while minimizing side effects.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2011</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">February 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To Compare Overall Survival of Patients Treated With CRLX101 + BSC to Those Patients Treated With BSC Only</measure>
    <time_frame>Up to 18 months</time_frame>
    <description>Comparison of survival among patients treated with CRLX101 + best supportive care vs patients treated wiht best supportive care only.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess Objective Response Rate (ORR) of CRLX101+ BSC Compared to BSC Only</measure>
    <time_frame>12 months</time_frame>
    <description>Comparison of objective response rate in subjects treated with CRLX101+BSC versus subjects treated with BSC alone.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">157</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>CRLX101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Best supportive care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CRLX101</intervention_name>
    <description>CRLX101 is administered at 15mg/m2 IV every other week</description>
    <arm_group_label>CRLX101</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Best Supportive Care</intervention_name>
    <description>best supportive care</description>
    <arm_group_label>Best supportive care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female patients who are ≥ 18-years of age.

          -  Histologically or cytologically confirmed, locally advanced or metastatic NSCLC
             (adenocarcinoma, bronchoalveolar, squamous cell, large cell, or mixed carcinoma) that
             is not amendable to surgical treatment and patient has have failed 1 or 2 different
             lines of chemotherapy.

          -  Measureable disease and evidence of progression on the previous therapy. Progression
             may be clinical or radiological.

          -  ECOG performance status of 0 or 1.

          -  Life expectancy of at least 3 months.

          -  Hemoglobin ≥ 10 g/dL.

          -  Absolute neutrophil count (ANC) ≥ 1500 cells/µL without growth factor support.

          -  Platelet count ≥ 100,000 cells/µL without support.

          -  Adequate hepatic and renal function including the following: Total bilirubin &lt; 2 ×
             ULN, AST or ALT ≤ 2.5 × ULN or ≤ 5 × ULN for patients with liver metastasis, PTT
             within normal limits, INR ≤ 1.5, Serum Creatinine &lt;1.5 ULN

          -  At least 4 weeks post any radiotherapy or biological therapy; at least 6 weeks post
             nitrosoureas therapy.

          -  Full recovery from diagnostic or therapeutic surgery (i.e., complete wound healing)
             and at least 30 days have elapsed prior to initial dosing.

          -  Full recovery from the toxic effects of prior therapy (i.e., Common Toxicity Criteria
             [CTC] Grade 1 or less with the exception of Grade 2 alopecia).

          -  Women of childbearing potential must have adequate pregnancy test. If postmenopausal,
             must be ≥ 12 months since last menses.

          -  Women of childbearing potential and men must agree to use an effective form of
             contraception during the study and for 60 days after the last dose of study drug.

        Exclusion Criteria:

          -  CNS metastases by radiologic evidence or histology, unless clinically stable (must
             have been treated by resection or radiation) for at least 4 weeks prior to first dose
             of study drug. Patients may not be receiving dexamethasone for control of CSF
             pressure.

          -  Concurrent therapeutic anticoagulation: PTT less than or equal to 1.5 × ULN or low
             dose aspirin and low-weight heparin only are allowed.

          -  More than 2 previous lines of chemotherapy for lung cancer. This includes biologic
             (immunotherapy) therapy.

          -  History of previous cerebrovascular accident (CVA) or history transient ischemic
             attack (TIA) within 6 months of study entry.

          -  History of prior malignancy not cured by excision. Patients with non-melanoma skin
             cancer or carcinoma in situ of the cervix are not excluded, but patients with other
             prior malignancies must have had at least 2-year disease free interval.

          -  Recent history (within 6 months of screening) of unstable angina, myocardial
             infarction, or NYHA Class III or IV congestive heart failure

          -  History of cardiac arrhythmia requiring medical or electrical therapy.

          -  QTc &gt; 450 msec for males and &gt; 470 msec for females.

          -  Any major surgery within 30 days or minor surgery within 10 days of study entry, or
             patient not recovered from surgery.

          -  History of organ or bone marrow transplant.

          -  Known active and/or uncontrolled infection, including HIV and are not stable on
             antiretroviral therapy.

          -  Any investigational therapy within 28 days of study entry.

          -  Pregnant or nursing.

          -  Anyone who in the judgment of the investigator cannot comply with the protocol,
             provide truly informed consent, or is likely to live &lt; 90 days

          -  Severe or significant allergy to any chemotherapy or premedication.

          -  Clinically evident ascites (e.g., abdominal distention, bulging and/or fluid wave) or
             Grade 3 peripheral edema.

          -  Any prior cancer treatment with a topoisomerase I inhibitor.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>NewLink Genetics</last_name>
    <role>Study Chair</role>
    <affiliation>NewLink Genetics Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>State Medical Institution Republican Oncology Center</name>
      <address>
        <city>Saransk</city>
        <state>Republic of Mordovia</state>
        <zip>430032</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Medical Institution Republic Clinical Oncological Center under the Healthcare Ministry of Tatarstan Republic</name>
      <address>
        <city>Kazan</city>
        <state>Republic of Tatarstan</state>
        <zip>420029</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arkhangelsk Regional Clinical Oncology Center</name>
      <address>
        <city>Arkhangelsk</city>
        <zip>163045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution: Bryansk Regional Oncology Center</name>
      <address>
        <city>Bryansk</city>
        <zip>241033</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chelyabinsk Regional Clinical Oncology Center</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kursk Regional Oncology Center</name>
      <address>
        <city>Kursk</city>
        <zip>305035</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institution of the Russian Academy of Medical Sciences Russian Oncological Research Center</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Non-Government Medical Institution: Central Clinical Hospital #2</name>
      <address>
        <city>Moscow</city>
        <zip>129128</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Healthcare Institution of Nizhny Novgorod Regiona Nizhny Novgorod Oncology Center</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603081</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital #1</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630047</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Medical Institution: Pyatigorsk Oncological Center</name>
      <address>
        <city>Pyatigorsk</city>
        <zip>357500</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Petersburg Medical University</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Oncology Center</name>
      <address>
        <city>St. Petersburg</city>
        <zip>198255</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stavropol Regional Clinical Oncology Center</name>
      <address>
        <city>Stavropol</city>
        <zip>355047</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tambov Regional Oncology Center</name>
      <address>
        <city>Tambov</city>
        <zip>392013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Primorsky Regional Oncology Center</name>
      <address>
        <city>Vladivostok</city>
        <zip>690105</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Oncology Center</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150054</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dnipropetrovsk State Medical Academy</name>
      <address>
        <city>Dnipropetrovsk</city>
        <zip>49102</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Public Treatment and Prophylaxis Institution; Donetsk Regional Antitumor Center</name>
      <address>
        <city>Donetsk</city>
        <zip>83092</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ivano-Frankovsk State Medical University; Oncology Department Clinical Facility</name>
      <address>
        <city>Ivano-Frankivsk</city>
        <zip>76000</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kharkiv State Public Healthcare Institution: Kharkiv Regional Clinical Oncology Center</name>
      <address>
        <city>Kharkiv</city>
        <zip>61070</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Khmelnytskyi Regional Oncology Center</name>
      <address>
        <city>Khmelnytsky</city>
        <zip>29009</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyiv City Oncology Hospital</name>
      <address>
        <city>Kyiv</city>
        <zip>03115</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sumy Regional Clinical Oncology Center</name>
      <address>
        <city>Sumy</city>
        <zip>40005</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Zakarpattia Regional Clinical Oncology Center</name>
      <address>
        <city>Uzhgorod</city>
        <zip>88011</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
    <country>Ukraine</country>
  </location_countries>
  <link>
    <url>http://www.ceruleanrx.com</url>
  </link>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 22, 2011</study_first_submitted>
  <study_first_submitted_qc>June 23, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 27, 2011</study_first_posted>
  <results_first_submitted>October 26, 2015</results_first_submitted>
  <results_first_submitted_qc>April 18, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 24, 2017</results_first_posted>
  <last_update_submitted>April 18, 2017</last_update_submitted>
  <last_update_submitted_qc>April 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Camptothecin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was conducted from 04 Jul 2011 to 07 Oct 2014. A total of 24 medical clinics participated in the study.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>CRLX101 + BSC (Best Supportive Care)</title>
          <description>15 mg/m2 CRLX101 infused IV over 60 minutes every other week + Standard therapy consisting of best supportive care (BSC), including at least blood and platelet transfusions, therapeutic radiation, and bone marrow support (granulocyte colony-stimulating factor [G-CSF]) as required.</description>
        </group>
        <group group_id="P2">
          <title>BSC (Best Supportive Care) Alone</title>
          <description>Standard therapy consisting of best supportive care (BSC), including at least blood and platelet transfusions, therapeutic radiation, and bone marrow support (granulocyte colony-stimulating factor [G-CSF]) as required.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="100"/>
                <participants group_id="P2" count="57"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="91">subjects in ITT with reported date of death, alive with progression, or alive without progression</participants>
                <participants group_id="P2" count="43">subjects in ITT with reported date of death, alive with progression, or alive without progression</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intention-to-treat (ITT) and Patient Safety Population (PSP), includes all CRLX101 + BSC subjects who received at least 1 dose of study treatment and all randomized BSC alone subjects who attended at least 1 study visit.</population>
      <group_list>
        <group group_id="B1">
          <title>CRLX101 + BSC (Best Supportive Care)</title>
          <description>15 mg/m2 CRLX101 infused IV over 60 minutes every other week + Standard therapy consisting of best supportive care (BSC), including at least blood and platelet transfusions, therapeutic radiation, and bone marrow support (granulocyte colony-stimulating factor [G-CSF]) as required.</description>
        </group>
        <group group_id="B2">
          <title>BSC (Best Supportive Care) Alone</title>
          <description>Standard therapy consisting of best supportive care (BSC), including at least blood and platelet transfusions, therapeutic radiation, and bone marrow support (granulocyte colony-stimulating factor [G-CSF]) as required.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="97"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="147"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58" spread="8.22"/>
                    <measurement group_id="B2" value="60.6" spread="6.42"/>
                    <measurement group_id="B3" value="59.4" spread="7.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="42"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="72"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Russian Federation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56"/>
                    <measurement group_id="B2" value="29"/>
                    <measurement group_id="B3" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ukraine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>To Compare Overall Survival of Patients Treated With CRLX101 + BSC to Those Patients Treated With BSC Only</title>
        <description>Comparison of survival among patients treated with CRLX101 + best supportive care vs patients treated wiht best supportive care only.</description>
        <time_frame>Up to 18 months</time_frame>
        <population>Intention-to-treat (ITT) and Patient Safety Population (PSP), includes all CRLX101 + BSC subjects who received at least 1 dose of study treatment and all randomized BSC alone subjects who attended at least 1 study visit. (Confidence interval if insufficient data to estimate NE = 99999.99)</population>
        <group_list>
          <group group_id="O1">
            <title>CRLX101</title>
            <description>CRLX101: CRLX101 is administered at 15mg/m2 IV every other week</description>
          </group>
          <group group_id="O2">
            <title>Best Supportive Care</title>
            <description>Best Supportive Care: best supportive care</description>
          </group>
        </group_list>
        <measure>
          <title>To Compare Overall Survival of Patients Treated With CRLX101 + BSC to Those Patients Treated With BSC Only</title>
          <description>Comparison of survival among patients treated with CRLX101 + best supportive care vs patients treated wiht best supportive care only.</description>
          <population>Intention-to-treat (ITT) and Patient Safety Population (PSP), includes all CRLX101 + BSC subjects who received at least 1 dose of study treatment and all randomized BSC alone subjects who attended at least 1 study visit. (Confidence interval if insufficient data to estimate NE = 99999.99)</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" lower_limit="4.70" upper_limit="8.68"/>
                    <measurement group_id="O2" value="11.9" lower_limit="6.74">Insufficient data to estimate</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assess Objective Response Rate (ORR) of CRLX101+ BSC Compared to BSC Only</title>
        <description>Comparison of objective response rate in subjects treated with CRLX101+BSC versus subjects treated with BSC alone.</description>
        <time_frame>12 months</time_frame>
        <population>Intention-To-Treat (ITT)</population>
        <group_list>
          <group group_id="O1">
            <title>CRLX101</title>
            <description>CRLX101: CRLX101 is administered at 15mg/m2 IV every other week</description>
          </group>
          <group group_id="O2">
            <title>Best Supportive Care</title>
            <description>Best Supportive Care: best supportive care</description>
          </group>
        </group_list>
        <measure>
          <title>Assess Objective Response Rate (ORR) of CRLX101+ BSC Compared to BSC Only</title>
          <description>Comparison of objective response rate in subjects treated with CRLX101+BSC versus subjects treated with BSC alone.</description>
          <population>Intention-To-Treat (ITT)</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="97"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.2"/>
                    <measurement group_id="O2" value="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>First dose to 30 days after the last dose of study drug</time_frame>
      <group_list>
        <group group_id="E1">
          <title>CRLX101+BSC</title>
          <description>15 mg/m2 CRLX101 infused IV over 60 minutes every other week + Standard therapy consisting of best supportive care, including at least blood and platelet transfusions, therapeutic radiation, and bone marrow support (granulocyte colony-stimulating factor [G-CSF]) as required.</description>
        </group>
        <group group_id="E2">
          <title>Best Supportive Care (BSC) Only</title>
          <description>Standard therapy consisting of best supportive care, including at least blood and platelet transfusions, therapeutic radiation, and bone marrow support (granulocyte colony-stimulating factor [G-CSF]) as required.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA, version 16.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>atrial flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>cardiopulmonary failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>dysphagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>anaphylatic reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>bronchitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>lung abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>pyothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>liver function test</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>psychotic disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>hematuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>esophagobronchial fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>pulmonary hemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>pulmonary thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>superior vena cava syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>3</frequency_threshold>
        <default_vocab>MedDRA, version 16.0</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="76" subjects_at_risk="97"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>anemia</sub_title>
                <counts group_id="E1" events="46" subjects_affected="25" subjects_at_risk="97"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>thrombocytopenia</sub_title>
                <counts group_id="E1" events="18" subjects_affected="5" subjects_at_risk="97"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>neutropenia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="4" subjects_at_risk="97"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>leukopenia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>sinus tachycardia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>nausea</sub_title>
                <counts group_id="E1" events="19" subjects_affected="11" subjects_at_risk="97"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>vomiting</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>diarrhea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>asthenia</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="97"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>fatigue</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="97"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>chest pain</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="97"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>pyrexia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="97"/>
                <counts group_id="E2" events="9" subjects_affected="5" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>edema peripheral</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>hyperbilirubinemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E2" events="5" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>pneumonia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="97"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="97"/>
                <counts group_id="E2" events="8" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="14" subjects_affected="8" subjects_at_risk="97"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>blood creatinine increased</sub_title>
                <counts group_id="E1" events="22" subjects_affected="5" subjects_at_risk="97"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>blood glucose increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Eastern Cooperative Oncology Group performance status worsened</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>decreased appetitie</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="97"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>hyperglycemia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>bone pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="97"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>pain in extremity</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="97"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>back pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>neck pain</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>non-small cell lung cancer</sub_title>
                <description>progression of disease</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="97"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>dizziness</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="97"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>cystitis</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="97"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>hematuria</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="97"/>
                <counts group_id="E2" events="4" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>leukocyturia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="5" subjects_at_risk="97"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>proteinuria</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="97"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>dyspnea</sub_title>
                <counts group_id="E1" events="19" subjects_affected="17" subjects_at_risk="97"/>
                <counts group_id="E2" events="14" subjects_affected="14" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>cough</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="97"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>hemoptysis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="7" subjects_at_risk="97"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>alopecia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>superior vena cava syndrome</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>hypertension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="97"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Investigator interested in participating in writing the manuscript should contact the Sponsor. The Investigsator shall not make any Study-related publication or other disclosure without the Sponsor's prior written approval, which may be withheld or granted by the Sponsor, in its sole discretion.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Adrian Senderowicz</name_or_title>
      <organization>Cerulean Pharma Inc.</organization>
      <phone>617 551 9600</phone>
      <email>asenderowicz@ceruleanrx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

